Edwards Lifesciences Corporation specializes in providing innovative products and technologies aimed at treating structural heart disease, as well as critical care and surgical monitoring solutions in various global markets including the United States, Europe, and Japan. The company recorded an operating income of $1,636,200,000.00 reflecting its earnings from core operations. It reported a substantial revenue of $6,067,600,000.00 showcasing its strong market presence in the industry. The company offers transcatheter heart valve replacement products, allowing for minimally invasive heart valve replacements, along with transcatheter valve repair and replacement products targeting mitral and tricuspid valve diseases. Additionally, the company provides the PASCAL and Cardioband transcatheter valve repair systems, which facilitate minimally-invasive therapies. In terms of surgical structural heart solutions, it offers solutions like the aortic surgical valve under the INSPIRIS name and KONECT RESILIA, a pre-assembled aortic tissue valved conduit designed for patients needing valve and root replacements alongside the ascending aorta. The HARPOON Beating Heart Mitral Valve Repair System is also available for patients suffering from degenerative mitral regurgitation. Furthermore, Edwards Lifesciences delivers critical care solutions including advanced hemodynamic monitoring systems that assess heart function and fluid status in surgical and intensive care settings, as well as the Acumen Hypotension Prediction Index software, which provides timely alerts to clinicians regarding dangerously low blood pressure. The company reported an income before tax of $1,272,900,000.00 showcasing its pre-tax profitability, and the operating income ratio stands at $0.27 indicating the company's operational profitability margin. In the financial market, the stock is reasonably priced at $74.41 appealing to a broad range of investors and reflecting the company’s robust standing. The stock has a high average trading volume of 3,832,540.00 indicating strong liquidity which can attract both new and seasoned investors. With a mid-range market capitalization of $44,543,279,048.00 the company continues to be a steady performer within its sector. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape while driving innovation and growth in the Healthcare sector.